Trials / Conditions / Recurrent Fallopian Tube Endometrioid Adenocarcinoma

Recurrent Fallopian Tube Endometrioid Adenocarcinoma

6 registered clinical trials studyying Recurrent Fallopian Tube Endometrioid Adenocarcinoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patien NCT05231122	Roswell Park Cancer Institute	Phase 2
Recruiting	Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity NCT05920798	Mayo Clinic	Phase 1 / Phase 2
Withdrawn	Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent NCT05295589	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurr NCT04034927	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R NCT02839707	National Cancer Institute (NCI)	Phase 2 / Phase 3